
Experimental pancreatic cancer drug doubles survival time in trial
NEWYou can now listen to Fox News articles!
Combining an experimental pill with standard chemotherapy shrank tumors or stopped growth in most patients with advanced pancreatic cancer, according to initial clinical trial results presented Friday at a major international cancer conference.
The results, shared at the EORTC-NCI-AACR symposium in Barcelona, come from a phase ½ trial testing a daily oral medication called daraxonrasib, as well as two standard intravenous chemotherapy drugs, gemcitabine and nab-paclitaxel.
The trial focused on 61 patients whose pancreatic cancer had already spread to other organs and who had not yet received treatment for their advanced disease.
PANCREATIC CANCER PATIENT BEN SASSE SEES “MASSIVE” TUMOR REDUCTION THANKS TO NEW EXPERIMENTAL DRUG
Pancreatic cancer is notoriously difficult to treat because more than half of patients are diagnosed after the disease has already spread, research shows.
In major clinical trials for metastatic pancreatic cancer, chemotherapy alone shrinks tumors in about 23 to 42 percent of patients, but the disease usually begins to grow again after five to six months and most patients survive between 8 and 11 months.

Combining an experimental daily pill called daraxonrasib with standard chemotherapy shrank tumors or stopped cancer growth in 90.2% of patients with untreated advanced pancreatic cancer. (iStock)
According to data from the National Cancer Institute, only about 3 percent of patients with late-stage disease live five years after diagnosis.
In the new study, which followed patients for a median of 18 months, tumors shrank in 60.7% of cases, including 8.2% where they disappeared entirely on scans. Overall, the combination stopped tumor growth in 90.2% of participants.
FDA APPROVES DAILY PILL FOR DEADLY CANCER AFTER PATIENT SURVIVAL RATES NEARLY DOUBLED
Patients took an average of 12.8 months before their cancer worsened, almost double the time typically seen with standard chemotherapy, and 76.6% were still alive after a year, the study found.
“We are now seeing not only substantial tumor shrinkage, including complete responses, but also durable disease control, with median progression-free survival exceeding one year,” said Dr. Wungki Park, study leader and gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, in a press release.

Most side effects, including rash, diarrhea, fatigue and low blood counts, were manageable with standard care, and only 5% of patients stopped treatment due to daraxonrasib. (iStock)
More than 90% of pancreatic cancers are caused by a faulty gene called RAS, which allows tumors to continue to grow. Daraxonrasib is designed to turn off this growth signal, something scientists have long thought impossible to correct with drugs.
Dr. Elena Garralda, chair of the symposium and co-director of the clinical research program at the Vall d’Hebron Oncology Institute in Spain, who was not involved in the research, said the results show that drugs targeting RAS can be combined with existing treatments early in treatment to potentially achieve longer-term benefits.
CLICK HERE FOR MORE HEALTH STORIES
Side effects included rash, diarrhea, fatigue, and chemotherapy-related low blood cell counts, most of which were manageable with standard care.
Only 5% of patients stopped treatment due to daraxonrasib-related side effects.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
The researchers noted that the results have some limitations.
As this was a single-group, early-phase study involving 61 people, all participants received the experimental combination. Without a direct comparison group of patients receiving only standard chemotherapy, doctors cannot yet confirm how much more effective the new regimen is or whether it permanently extends overall survival.

Researchers are currently conducting a larger phase 3 randomized trial to directly compare the new treatment to standard chemotherapy. (iStock)
The findings also apply strictly to metastatic pancreatic cancer, although RAS mutations cause several other cancers, including some lung, colorectal, and gynecologic cancers. Separate studies would be needed to test whether the combination works in these diseases.
CLICK HERE TO SUBSCRIBE TO OUR HEALTH NEWSLETTER
The trial was funded by Revolution Medicines, the California developer of daraxonrasib.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
To determine whether these initial results translate into a lasting survival benefit, researchers launched a larger randomized phase 3 trial, called RASolute-303, which directly compares daraxonrasib – alone or combined with chemotherapy – to standard chemotherapy alone.
Gn Health